| (GSK) 221530 / JADE | A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma | Dr Baskoro (Adi) Kartolo | Open to recruitment | NCT06256588 |
| (JCC) SHINE / HNSBRT | A Phase 2 Study of SBRT for Squamous Cell Carcinoma of the Head and Neck | Dr Justin Lee | Open to recruitment | NCT04435938 |
| (Merck) MK-7902-009 | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (LEAP-009) | Dr Baskoro (Adi) Kartolo | Open to recruitment | NCT04428151 |
Find a Trial
Contact Us